Oncolytics Biotech (ONCY)
(Real Time Quote from BATS)
$1.04 USD
+0.01 (0.97%)
Updated Mar 28, 2024 11:32 AM ET
2-Buy of 5 2
D Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ONCY 1.04 +0.01(0.97%)
Will ONCY be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCY
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
New Strong Buy Stocks for January 18th
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
2 Sector ETFs Hovering Around a 52-Week High
What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?
Other News for ONCY
Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
Maintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership Potential
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials